Biotech Values

[DewDiligence]

Looks like Merck will not file the NDA [for Rolofylline] in 2009

The PR reads as though the Rolofylline program is dead—there is no mention of the second phase-3 trial in HF, as one would expect if MRK had any intention of salvaging the program. (See drbio’s post in #msg-38457021.)

Not much has gone right for MRK lately, but the stock is nevertheless up 30% from its March low.